Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för George A Scangos. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att George A Scangos har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:A / Agilent Technologies, Inc. | Director | 20 493 |
US:VIR / Vir Biotechnology, Inc. | Director | 698 239 |
US:EXEL / Exelixis, Inc. | Director | 714 717 |
US:BIIB / Biogen Inc. | Chief Executive Officer, Director | 54 779 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av George A Scangos. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp VIR / Vir Biotechnology, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i VIR / Vir Biotechnology, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i VIR / Vir Biotechnology, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av George A Scangos som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-18 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
A - Award | 1 819 | 20 493 | 9,74 | 121,18 | 220 426 | 2 483 351 | |
2025-02-25 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | −10 056 | 698 239 | −1,42 | 9,45 | −95 063 | 6 600 733 | |
2025-02-19 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | −10 964 | 708 295 | −1,52 | 9,81 | −107 575 | 6 949 578 | |
2024-10-24 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −598 270 | 1 151 730 | −34,19 | ||||
2024-10-24 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −598 270 | 1 151 730 | −34,19 | ||||
2024-10-24 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | 598 270 | 598 270 | |||||
2024-10-24 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | 598 270 | 598 270 | |||||
2024-06-03 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
A - Award | 8 000 | 120 989 | 7,08 | ||||
2024-05-31 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
G - Gift | 3 443 | 17 893 | 23,83 | 145,48 | 500 888 | 2 603 074 | |
2024-05-31 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
G - Gift | −3 443 | 18 578 | −15,64 | 145,48 | −500 888 | 2 702 709 | |
2024-03-19 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
A - Award | 1 678 | 21 989 | 8,26 | 147,48 | 247 471 | 3 242 990 | |
2024-02-26 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | X | −17 722 | 112 989 | −13,56 | 11,65 | −206 522 | 1 316 706 |
2024-02-26 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | −10 028 | 130 711 | −7,13 | 10,05 | −100 737 | 1 313 070 | |
2024-02-20 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | X | −16 872 | 140 739 | −10,70 | 10,22 | −172 385 | 1 437 959 |
2024-02-20 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | −10 878 | 157 611 | −6,46 | 10,24 | −111 386 | 1 613 874 | |
2023-10-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | 1 750 000 | 1 750 000 | |||||
2023-10-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | 1 750 000 | 1 750 000 | |||||
2023-10-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −1 750 000 | 0 | −100,00 | ||||
2023-10-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −1 750 000 | 0 | −100,00 | ||||
2023-09-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −827 151 | 0 | −100,00 | ||||
2023-09-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −827 151 | 0 | −100,00 | ||||
2023-09-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −111 644 | 0 | −100,00 | ||||
2023-09-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −111 644 | 0 | −100,00 | ||||
2023-09-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | 1 750 000 | 1 750 000 | |||||
2023-09-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | 1 750 000 | 1 750 000 | |||||
2023-09-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −3 500 000 | 33 629 | −99,05 | ||||
2023-03-20 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
A - Award | 1 658 | 20 185 | 8,95 | 136,82 | 226 848 | 2 761 700 | |
2023-02-24 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | X | −10 880 | 168 489 | −6,07 | 23,56 | −256 300 | 3 969 095 |
2023-02-24 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | X | −4 239 | 179 369 | −2,31 | 22,74 | −96 382 | 4 078 313 |
2023-02-24 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | −12 631 | 183 608 | −6,44 | 25,97 | −328 065 | 4 768 851 | |
2023-02-21 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | X | −6 474 | 196 239 | −3,19 | 28,80 | −186 451 | 5 651 683 |
2023-02-21 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | X | −11 382 | 202 713 | −5,32 | 28,02 | −318 867 | 5 679 005 |
2023-02-21 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | −9 894 | 214 095 | −4,42 | 25,29 | −250 199 | 5 414 034 | |
2023-02-21 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | 64 930 | 179 930 | 56,46 | ||||
2023-02-21 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −64 930 | 3 533 629 | −1,80 | ||||
2023-02-21 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | 49 984 | 111 644 | 81,06 | ||||
2023-02-21 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | 49 984 | 111 644 | 81,06 | ||||
2023-02-21 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −49 984 | 827 151 | −5,70 | ||||
2023-02-21 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −49 984 | 827 151 | −5,70 | ||||
2022-04-06 |
|
4 | VIR |
Vir Biotechnology, Inc.
Stock Option (Right to Buy) |
A - Award | 222 000 | 222 000 | |||||
2022-04-06 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
A - Award | 111 000 | 223 989 | 98,24 | ||||
2022-03-21 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
A - Award | 1 785 | 18 420 | 10,73 | 136,82 | 244 224 | 2 520 206 | |
2022-02-22 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | X | −17 726 | 112 989 | −13,56 | 30,65 | −543 304 | 3 463 124 |
2022-02-22 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
S - Sale | −10 024 | 130 715 | −7,12 | 31,93 | −320 074 | 4 173 835 | |
2022-02-14 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | 29 739 | 140 739 | 26,79 | ||||
2022-02-14 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | 877 135 | 877 135 | |||||
2022-02-14 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | 877 135 | 877 135 | |||||
2022-02-14 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | 61 660 | 61 660 | |||||
2022-02-14 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | 61 660 | 61 660 | |||||
2022-02-14 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | −1 907 329 | 0 | −100,00 | ||||
2022-02-14 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | 3 598 559 | 3 598 559 | |||||
2022-02-14 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | −3 598 559 | 111 000 | −97,01 | ||||
2022-02-14 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | −900 000 | 3 709 559 | −19,52 | ||||
2021-03-22 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
A - Award | 986 | 16 544 | 6,34 | 121,59 | 119 891 | 2 011 599 | |
2021-03-22 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
A - Award | 1 850 | 15 558 | 13,50 | 121,59 | 224 947 | 1 891 709 | |
2021-02-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Stock Option (Right to Buy) |
A - Award | 222 000 | 222 000 | |||||
2021-02-18 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
A - Award | 111 000 | 4 609 559 | 2,47 | ||||
2021-02-12 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | −100 000 | 4 498 559 | −2,17 | ||||
2021-02-12 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | 115 000 | 115 000 | |||||
2021-02-12 |
|
5 | VIR |
Vir Biotechnology, Inc.
Common Stock |
G - Gift | −115 000 | 4 598 559 | −2,44 | ||||
2020-08-05 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
A - Award | 177 | 28 112 | 0,63 | 93,91 | 16 622 | 2 640 013 | |
2020-05-20 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −75 000 | 714 717 | −9,50 | 25,96 | −1 947 000 | 18 554 053 |
2020-05-15 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
M - Exercise | −21 686 | 0 | −100,00 | ||||
2020-05-15 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
M - Exercise | −30 000 | 0 | −100,00 | ||||
2020-05-15 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
M - Exercise | 21 686 | 789 717 | 2,82 | 5,82 | 126 213 | 4 596 153 | |
2020-05-15 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
M - Exercise | 30 000 | 768 031 | 4,06 | 4,58 | 137 400 | 3 517 582 | |
2020-04-24 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −15 000 | 738 031 | −1,99 | 26,24 | −393 600 | 19 365 933 |
2020-04-24 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −55 700 | 753 031 | −6,89 | 26,23 | −1 461 011 | 19 752 003 |
2020-04-24 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −44 300 | 808 731 | −5,19 | 25,68 | −1 137 624 | 20 768 212 |
2020-04-22 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −4 200 | 853 031 | −0,49 | 25,05 | −105 210 | 21 368 427 |
2020-04-22 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −5 800 | 857 231 | −0,67 | 25,04 | −145 232 | 21 465 064 |
2020-04-22 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −5 900 | 863 031 | −0,68 | 24,70 | −145 730 | 21 316 866 |
2020-04-22 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −25 600 | 868 931 | −2,86 | 24,07 | −616 192 | 20 915 169 |
2020-04-22 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −18 500 | 894 531 | −2,03 | 23,39 | −432 715 | 20 923 080 |
2020-04-21 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
A - Award | 1 027 | 27 887 | 3,82 | 73,01 | 74 980 | 2 036 035 | |
2020-04-21 |
|
4 | A |
AGILENT TECHNOLOGIES, INC.
Common Stock |
A - Award | 3 081 | 26 860 | 12,96 | 73,01 | 224 941 | 1 961 055 | |
2020-04-17 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −25 000 | 913 031 | −2,67 | 18,31 | −457 750 | 16 717 598 |
2020-04-16 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | 236 806 | 4 713 559 | 5,29 | 29,56 | 6 999 985 | 139 332 804 | |
2020-04-16 |
|
4 | VIR |
Vir Biotechnology, Inc.
Common Stock |
J - Other | −236 806 | 1 907 329 | −11,04 | 29,56 | −6 999 985 | 56 380 645 | |
2020-04-09 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −7 065 | 938 031 | −0,75 | 18,35 | −129 643 | 17 212 869 |
2020-04-09 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −16 435 | 945 096 | −1,71 | 18,25 | −299 939 | 17 248 002 |
2020-04-02 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −1 500 | 961 531 | −0,16 | 18,06 | −27 090 | 17 365 250 |
2020-02-21 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −50 000 | 963 031 | −4,94 | 20,73 | −1 036 500 | 19 963 633 |
2020-02-12 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −21 000 | 1 013 031 | −2,03 | 20,02 | −420 420 | 20 280 881 |
2020-02-12 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −4 000 | 1 034 031 | −0,39 | 20,14 | −80 560 | 20 825 384 |
2020-01-24 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −25 000 | 1 038 031 | −2,35 | 19,75 | −493 750 | 20 501 112 |
2020-01-17 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −25 000 | 1 063 031 | −2,30 | 20,39 | −509 750 | 21 675 202 |
2019-12-27 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −25 000 | 1 090 531 | −2,24 | 18,25 | −456 250 | 19 902 191 |
2019-12-27 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
G - Gift | −12 500 | 1 115 531 | −1,11 | ||||
2019-10-10 | 3 | VIR |
Vir Biotechnology, Inc.
Common Stock |
11 019 554 | ||||||||
2019-10-10 | 3 | VIR |
Vir Biotechnology, Inc.
Common Stock |
8 843 110 | ||||||||
2019-10-10 | 3 | VIR |
Vir Biotechnology, Inc.
Common Stock |
11 019 554 | ||||||||
2019-10-10 | 3 | VIR |
Vir Biotechnology, Inc.
Common Stock |
8 843 110 | ||||||||
2019-10-10 | 3 | VIR |
Vir Biotechnology, Inc.
Common Stock |
11 019 554 | ||||||||
2019-10-10 | 3 | VIR |
Vir Biotechnology, Inc.
Common Stock |
8 843 110 | ||||||||
2019-08-02 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −6 050 | 1 128 031 | −0,53 | 21,23 | −128 442 | 23 948 098 |
2019-08-02 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −33 950 | 1 134 081 | −2,91 | 20,48 | −695 296 | 23 225 979 |
2019-07-03 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −40 000 | 1 168 031 | −3,31 | 21,58 | −863 200 | 25 206 109 |
2019-06-05 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −15 000 | 1 208 031 | −1,23 | 20,00 | −300 000 | 24 160 620 |
2019-06-05 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −25 000 | 1 223 031 | −2,00 | 19,61 | −490 250 | 23 983 638 |
2019-05-24 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
A - Award | 42 641 | 42 641 | |||||
2019-05-22 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
M - Exercise | −15 000 | 0 | −100,00 | ||||
2019-05-22 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
M - Exercise | 15 000 | 1 248 031 | 1,22 | 4,57 | 68 550 | 5 703 502 | |
2019-05-03 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −15 000 | 1 233 031 | −1,20 | 20,00 | −300 000 | 24 660 620 |
2019-05-03 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −25 000 | 1 248 031 | −1,96 | 19,75 | −493 750 | 24 648 612 |
2019-04-03 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −5 000 | 1 273 031 | −0,39 | 25,03 | −125 150 | 31 863 966 |
2019-04-03 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −40 000 | 1 278 031 | −3,03 | 24,02 | −960 800 | 30 698 305 |
2019-03-22 |
|
4 | A |
AGILENT TECHNOLOGIES INC
Common Stock |
A - Award | 1 255 | 23 699 | 5,59 | 82,00 | 102 899 | 1 943 309 | |
2019-03-22 |
|
4 | A |
AGILENT TECHNOLOGIES INC
Common Stock |
A - Award | 2 823 | 22 444 | 14,39 | 82,00 | 231 486 | 1 840 409 | |
2019-03-15 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −5 000 | 1 318 031 | −0,38 | 25,00 | −125 000 | 32 950 775 |
2019-03-01 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −40 000 | 1 323 031 | −2,93 | 22,66 | −906 400 | 29 979 882 |
2019-02-01 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −40 000 | 1 363 031 | −2,85 | 23,53 | −941 200 | 32 072 119 |
2019-01-04 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −96 | 1 403 031 | −0,01 | 20,00 | −1 920 | 28 060 620 |
2019-01-04 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −39 904 | 1 403 127 | −2,77 | 19,64 | −783 715 | 27 557 414 |
2019-01-04 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
G - Gift | −9 300 | 1 443 031 | −0,64 | ||||
2019-01-04 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
G - Gift | −4 650 | 1 452 331 | −0,32 | ||||
2018-12-03 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −40 000 | 1 456 981 | −2,67 | 21,16 | −846 400 | 30 829 718 |
2018-12-03 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −8 500 | 1 496 981 | −0,56 | 20,00 | −170 000 | 29 939 620 |
2018-12-03 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −6 500 | 1 505 481 | −0,43 | 20,00 | −130 000 | 30 109 620 |
2018-11-02 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −10 000 | 1 511 981 | −0,66 | 14,14 | −141 400 | 21 379 411 |
2018-11-02 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −15 000 | 1 521 981 | −0,98 | 15,00 | −225 000 | 22 829 715 |
2018-10-03 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | X | −25 000 | 1 536 981 | −1,60 | 17,86 | −446 500 | 27 450 481 |
2018-09-26 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | −25 000 | 1 561 981 | −1,58 | 16,85 | −421 250 | 26 319 380 | |
2018-08-10 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
M - Exercise | −33 333 | 0 | −100,00 | ||||
2018-08-10 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
M - Exercise | −75 000 | 0 | −100,00 | ||||
2018-08-10 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
M - Exercise | 33 333 | 1 586 981 | 2,15 | 4,42 | 147 332 | 7 014 456 | |
2018-08-10 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
M - Exercise | 75 000 | 1 553 648 | 5,07 | 5,04 | 378 000 | 7 830 386 | |
2018-05-24 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
A - Award | 31 167 | 31 167 | |||||
2018-05-16 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
M - Exercise | −15 000 | 0 | −100,00 | ||||
2018-05-16 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
M - Exercise | 15 000 | 1 478 648 | 1,02 | 11,66 | 174 900 | 17 241 036 | |
2018-03-23 |
|
4 | A |
AGILENT TECHNOLOGIES INC
Common Stock |
A - Award | 1 438 | 19 574 | 7,93 | 67,47 | 97 026 | 1 320 648 | |
2018-03-23 |
|
4 | A |
AGILENT TECHNOLOGIES INC
Common Stock |
A - Award | 2 876 | 18 136 | 18,85 | 67,47 | 194 044 | 1 223 622 | |
2017-05-26 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
A - Award | 23 491 | 23 491 | |||||
2017-03-17 |
|
4 | A |
AGILENT TECHNOLOGIES INC
Common Stock |
A - Award | 3 866 | 15 253 | 33,95 | 53,05 | 205 091 | 809 167 | |
2016-12-07 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
M - Exercise | −356 | 0 | −100,00 | ||||
2016-12-07 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | −176 | 1 463 648 | −0,01 | 17,90 | −3 150 | 26 199 299 | |
2016-12-07 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
M - Exercise | 356 | 1 463 824 | 0,02 | 8,99 | 3 200 | 13 159 778 | |
2016-12-07 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
M - Exercise | −357 976 | 356 | −99,90 | ||||
2016-12-07 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
S - Sale | −204 718 | 1 463 468 | −12,27 | 17,81 | −3 646 028 | 26 064 365 | |
2016-12-07 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
M - Exercise | 357 976 | 1 668 186 | 27,32 | 8,99 | 3 218 204 | 14 996 992 | |
2016-07-22 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −157 | 54 779 | −0,29 | 280,00 | −43 960 | 15 338 120 |
2016-06-06 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −842 | 54 936 | −1,51 | 290,00 | −244 180 | 15 931 440 |
2016-06-02 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −487 | 55 778 | −0,87 | 287,97 | −140 241 | 16 062 391 |
2016-06-02 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −3 368 | 56 265 | −5,65 | 290,00 | −976 720 | 16 316 850 |
2016-05-27 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −157 | 59 633 | −0,26 | 280,00 | −43 960 | 16 697 240 |
2016-05-26 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
A - Award | 40 000 | 40 000 | |||||
2016-05-04 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −487 | 59 790 | −0,81 | 274,74 | −133 798 | 16 426 705 |
2016-04-07 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −157 | 60 277 | −0,26 | 280,00 | −43 960 | 16 877 560 |
2016-04-05 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −487 | 60 434 | −0,80 | 258,83 | −126 050 | 15 642 132 |
2016-03-18 |
|
4 | A |
AGILENT TECHNOLOGIES INC
Common Stock |
A - Award | 4 704 | 11 378 | 70,48 | 39,29 | 184 820 | 447 058 | |
2016-03-03 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −487 | 60 921 | −0,79 | 261,37 | −127 287 | 15 922 922 |
2016-03-03 |
|
4/A | BIIB |
BIOGEN INC.
Restricted Stock Unit |
M - Exercise | −9 189 | 18 380 | −33,33 | ||||
2016-03-03 |
|
4/A | BIIB |
BIOGEN INC.
Common Stock |
M - Exercise | 9 189 | 43 466 | 26,81 | ||||
2016-02-25 |
|
4 | BIIB |
BIOGEN INC.
Restricted Stock Unit |
J - Other | −5 884 | 17 702 | −24,95 | ||||
2016-02-25 |
|
4 | BIIB |
BIOGEN INC.
Restricted Stock Unit |
M - Exercise | −2 964 | 23 586 | −11,16 | ||||
2016-02-25 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
F - Taxes | −1 395 | 61 417 | −2,22 | 258,99 | −361 291 | 15 906 389 | |
2016-02-25 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
M - Exercise | 2 964 | 62 812 | 4,95 | ||||
2016-02-24 |
|
4 | BIIB |
BIOGEN INC.
Restricted Stock Unit |
A - Award | 40 460 | 40 460 | |||||
2016-02-19 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −487 | 59 848 | −0,81 | 256,16 | −124 750 | 15 330 664 |
2016-02-17 |
|
4 | BIIB |
BIOGEN INC.
Restricted Stock Unit |
J - Other | −5 982 | 10 502 | −36,29 | ||||
2016-02-17 |
|
4 | BIIB |
BIOGEN INC.
Restricted Stock Unit |
M - Exercise | −9 189 | 9 182 | −50,02 | ||||
2016-02-17 |
|
4 | BIIB |
BIOGEN INC.
Restricted Stock Unit |
M - Exercise | −4 512 | 16 484 | −21,49 | ||||
2016-02-17 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
F - Taxes | −5 359 | 60 335 | −8,16 | 247,22 | −1 324 852 | 14 916 019 | |
2016-02-17 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
A - Award | 11 390 | 65 694 | 20,97 | ||||
2016-02-17 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
F - Taxes | −4 324 | 54 304 | −7,38 | 247,22 | −1 068 979 | 13 425 035 | |
2016-02-17 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
M - Exercise | 9 189 | 58 628 | 18,59 | ||||
2016-02-17 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
F - Taxes | −2 132 | 49 439 | −4,13 | 247,22 | −527 073 | 12 222 310 | |
2016-02-17 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
M - Exercise | 4 512 | 51 571 | 9,59 | ||||
2016-02-10 |
|
4 | BIIB |
BIOGEN INC.
Restricted Stock Unit |
M - Exercise | −11 274 | 0 | −100,00 | ||||
2016-02-10 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
F - Taxes | −5 305 | 47 059 | −10,13 | 249,99 | −1 326 197 | 11 764 279 | |
2016-02-10 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
M - Exercise | 11 274 | 52 364 | 27,44 | ||||
2016-01-05 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
A - Award | 6 383 | 1 310 210 | 0,49 | ||||
2015-06-02 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −1 362 | 41 090 | −3,21 | 398,87 | −543 261 | 16 389 568 |
2015-05-28 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
A - Award | 40 000 | 40 000 | |||||
2015-05-05 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −1 362 | 42 452 | −3,11 | 377,52 | −514 182 | 16 026 479 |
2015-04-02 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
S - Sale | X | −1 362 | 43 814 | −3,01 | 423,20 | −576 398 | 18 542 085 |
2015-03-20 |
|
4 | A |
AGILENT TECHNOLOGIES INC
Common Stock |
A - Award | 4 311 | 6 666 | 183,06 | 42,21 | 181 967 | 281 373 | |
2015-03-16 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −537 | 45 176 | −1,17 | 412,69 | −221 613 | 18 643 593 |
2015-03-03 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −825 | 45 713 | −1,77 | 410,67 | −338 803 | 18 772 958 |
2015-02-25 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
A - Award | 26 550 | 26 550 | |||||
2015-02-20 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −537 | 46 538 | −1,14 | 401,04 | −215 358 | 18 663 600 |
2015-02-18 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −825 | 47 075 | −1,72 | 389,11 | −321 016 | 18 317 353 |
2015-02-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
J - Other | −4 093 | 20 996 | −16,31 | ||||
2015-02-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −6 401 | 25 089 | −20,33 | ||||
2015-02-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −9 198 | 18 371 | −33,36 | ||||
2015-02-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −4 781 | 47 900 | −9,08 | 392,11 | −1 874 678 | 18 782 069 | |
2015-02-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
A - Award | 10 149 | 52 681 | 23,86 | ||||
2015-02-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −3 015 | 42 532 | −6,62 | 392,11 | −1 182 212 | 16 677 223 | |
2015-02-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 6 401 | 45 547 | 16,35 | ||||
2015-02-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −4 329 | 39 146 | −9,96 | 392,11 | −1 697 444 | 15 349 538 | |
2015-02-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 9 198 | 43 475 | 26,83 | ||||
2015-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −18 833 | 0 | −100,00 | ||||
2015-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −8 871 | 34 277 | −20,56 | 395,13 | −3 505 198 | 13 543 871 | |
2015-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 18 833 | 43 148 | 77,45 | ||||
2015-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −11 270 | 11 274 | −49,99 | ||||
2015-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −4 940 | 24 315 | −16,89 | 396,88 | −1 960 587 | 9 650 137 | |
2015-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 11 270 | 29 255 | 62,66 | ||||
2014-11-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 128 | 17 985 | −5,90 | 320,78 | −361 840 | 5 769 228 |
2014-10-16 |
|
4 | EXEL |
EXELIXIS, INC.
Common Stock |
A - Award | 29 412 | 1 303 827 | 2,31 | ||||
2014-10-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 127 | 19 113 | −5,57 | 330,97 | −373 003 | 6 325 830 |
2014-09-18 |
|
4 | A |
AGILENT TECHNOLOGIES INC
Common Stock |
A - Award | 784 | 2 353 | 49,97 | 58,89 | 46 170 | 138 568 | |
2014-09-18 |
|
4 | A |
AGILENT TECHNOLOGIES INC
Common Stock |
A - Award | 1 569 | 1 569 | 58,89 | 92 398 | 92 398 | ||
2014-09-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 128 | 20 240 | −5,28 | 345,47 | −389 690 | 6 992 313 |
2014-08-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 128 | 21 368 | −5,01 | 332,93 | −375 545 | 7 114 048 |
2014-07-18 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −12 316 | 22 496 | −35,38 | 312,37 | −3 847 149 | 7 027 076 |
2014-07-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −21 339 | 0 | −100,00 | ||||
2014-07-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −10 062 | 34 812 | −22,42 | 312,00 | −3 139 344 | 10 861 344 | |
2014-07-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 21 339 | 44 874 | 90,67 | ||||
2014-06-03 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −484 | 23 535 | −2,02 | 318,93 | −154 362 | 7 506 018 |
2014-05-30 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
A - Award | 40 000 | 40 000 | |||||
2014-05-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −995 | 24 019 | −3,98 | 285,49 | −284 063 | 6 857 184 |
2014-05-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −642 | 25 014 | −2,50 | 285,43 | −183 246 | 7 139 746 |
2014-05-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −486 | 25 656 | −1,86 | 285,87 | −138 933 | 7 334 281 |
2014-04-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −2 123 | 26 142 | −7,51 | 308,42 | −654 776 | 8 062 716 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −100 | 28 265 | −0,35 | 338,05 | −33 805 | 9 554 983 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −2 065 | 28 365 | −6,79 | 337,25 | −696 421 | 9 566 096 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −3 001 | 30 430 | −8,98 | 336,49 | −1 009 806 | 10 239 391 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −3 985 | 33 431 | −10,65 | 335,25 | −1 335 971 | 11 207 743 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −5 673 | 37 416 | −13,17 | 334,54 | −1 897 845 | 12 517 149 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −2 300 | 43 089 | −5,07 | 333,61 | −767 303 | 14 374 921 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −3 280 | 45 389 | −6,74 | 332,40 | −1 090 272 | 15 087 304 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −2 420 | 48 669 | −4,74 | 331,55 | −802 351 | 16 136 207 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −900 | 51 089 | −1,73 | 330,65 | −297 585 | 16 892 578 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −500 | 51 989 | −0,95 | 329,06 | −164 530 | 17 107 500 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 200 | 52 489 | −2,24 | 328,38 | −394 056 | 17 236 338 |
2014-03-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −700 | 53 689 | −1,29 | 327,76 | −229 432 | 17 597 107 |
2014-03-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −486 | 54 389 | −0,89 | 335,79 | −163 194 | 18 263 282 |
2014-03-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 493 | 54 875 | −2,65 | 335,79 | −501 334 | 18 426 476 |
2014-03-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −963 | 56 368 | −1,68 | 335,79 | −323 366 | 18 927 811 |
2014-02-14 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −486 | 57 331 | −0,84 | 316,81 | −153 970 | 18 163 034 |
2014-02-14 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
A - Award | 31 490 | 31 490 | |||||
2014-02-14 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −9 189 | 27 569 | −25,00 | ||||
2014-02-14 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −4 333 | 57 817 | −6,97 | 323,04 | −1 399 732 | 18 677 204 | |
2014-02-14 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 9 189 | 62 150 | 17,35 | ||||
2014-02-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 493 | 52 961 | −2,74 | 314,31 | −469 265 | 16 646 172 |
2014-02-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −963 | 54 454 | −1,74 | 314,31 | −302 681 | 17 115 437 |
2014-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −18 833 | 18 833 | −50,00 | ||||
2014-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −8 880 | 55 417 | −13,81 | 315,54 | −2 801 995 | 17 486 280 | |
2014-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 18 833 | 64 297 | 41,42 | ||||
2014-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −11 270 | 22 544 | −33,33 | ||||
2014-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −4 850 | 45 464 | −9,64 | 315,54 | −1 530 369 | 14 345 711 | |
2014-02-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 11 270 | 50 314 | 28,86 | ||||
2013-12-09 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
A - Award | 21 686 | 21 686 | |||||
2013-11-05 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 112 | 39 044 | −2,77 | 245,57 | −273 074 | 9 588 035 |
2013-11-05 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 127 | 40 156 | −2,73 | 245,57 | −276 757 | 9 861 109 |
2013-10-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 112 | 41 283 | −2,62 | 242,85 | −270 049 | 10 025 577 |
2013-10-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 127 | 42 395 | −2,59 | 242,85 | −273 692 | 10 295 626 |
2013-09-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −200 | 43 522 | −0,46 | 216,31 | −43 262 | 9 414 244 |
2013-09-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −912 | 43 722 | −2,04 | 213,30 | −194 530 | 9 325 903 |
2013-09-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −300 | 44 634 | −0,67 | 216,26 | −64 876 | 9 652 326 |
2013-09-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −600 | 44 934 | −1,32 | 214,74 | −128 843 | 9 649 037 |
2013-09-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −227 | 45 534 | −0,50 | 213,80 | −48 531 | 9 734 942 |
2013-08-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −2 239 | 45 761 | −4,66 | 218,82 | −489 938 | 10 013 422 |
2013-07-18 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −2 239 | 48 000 | −4,46 | 223,94 | −501 402 | 10 749 120 |
2013-07-16 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −21 339 | 21 339 | −50,00 | ||||
2013-07-16 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −9 938 | 50 239 | −16,51 | 224,33 | −2 229 392 | 11 270 115 | |
2013-07-16 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −10 073 | 60 177 | −14,34 | 224,33 | −2 259 676 | 13 499 506 | |
2013-07-16 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 21 339 | 70 250 | 43,63 | ||||
2013-06-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 598 | 48 911 | −3,16 | 234,16 | −374 188 | 11 453 000 |
2013-05-24 |
|
4 | EXEL |
EXELIXIS, INC.
Option (right to buy) |
A - Award | 30 000 | 30 000 | |||||
2013-05-03 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 598 | 50 509 | −3,07 | 215,39 | −344 193 | 10 879 134 |
2013-04-03 |
|
4/A | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 598 | 52 107 | −2,98 | 193,66 | −309 469 | 10 091 042 |
2013-04-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 598 | 52 107 | −2,98 | 193,66 | −309 469 | 10 091 042 |
2013-03-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 598 | 53 705 | −2,89 | 165,30 | −264 149 | 8 877 436 |
2013-02-14 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 598 | 55 303 | −2,81 | 163,39 | −261 097 | 9 035 957 |
2013-02-14 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
A - Award | 36 758 | 36 758 | |||||
2013-02-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −18 833 | 37 666 | −33,33 | ||||
2013-02-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −8 890 | 56 901 | −13,51 | 164,44 | −1 461 872 | 9 356 800 | |
2013-02-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 18 833 | 65 791 | 40,11 | ||||
2013-02-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
J - Other | −1 503 | 33 814 | −4,26 | ||||
2013-02-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −9 767 | 35 317 | −21,66 | ||||
2013-02-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −3 723 | 46 958 | −7,35 | 164,44 | −612 210 | 7 721 774 | |
2013-02-12 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 9 767 | 50 681 | 23,87 | ||||
2013-01-24 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
G - Gift | 5 378 | 5 378 | |||||
2013-01-24 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
G - Gift | −5 378 | 40 914 | −11,62 | ||||
2013-01-24 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
G - Gift | 5 378 | 5 378 | |||||
2013-01-24 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
G - Gift | −5 378 | 46 292 | −10,41 | ||||
2012-11-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −828 | 51 670 | −1,58 | 139,73 | −115 698 | 7 219 952 |
2012-11-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −400 | 52 498 | −0,76 | 138,64 | −55 456 | 7 278 323 |
2012-11-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 244 | 52 898 | −2,30 | 139,46 | −173 486 | 7 377 049 |
2012-10-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −3 654 | 54 142 | −6,32 | 149,16 | −545 031 | 8 075 821 |
2012-09-05 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −3 654 | 57 796 | −5,95 | 145,90 | −533 119 | 8 432 436 |
2012-08-02 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −3 655 | 61 450 | −5,61 | 146,30 | −534 726 | 8 990 135 |
2012-07-18 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 228 | 65 105 | −1,85 | 146,04 | −179 337 | 9 507 934 |
2012-07-18 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 244 | 66 333 | −1,84 | 146,04 | −181 674 | 9 687 271 |
2012-07-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −21 339 | 42 678 | −33,33 | ||||
2012-07-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −8 780 | 67 577 | −11,50 | 144,61 | −1 269 676 | 9 772 310 | |
2012-07-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −8 899 | 76 357 | −10,44 | 144,61 | −1 286 884 | 11 041 986 | |
2012-07-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 21 339 | 85 256 | 33,39 | ||||
2012-07-03 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 183 | 63 917 | −1,82 | 143,50 | −169 760 | 9 172 090 |
2012-06-04 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | −1 183 | 65 100 | −1,78 | 128,63 | −152 169 | 8 373 813 |
2012-05-25 |
|
4 | EXEL |
EXELIXIS INC
Option (right to buy) |
A - Award | 15 000 | 15 000 | |||||
2012-02-22 |
|
4/A | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −8 791 | 54 374 | −13,92 | 104,00 | −914 264 | 5 654 896 | |
2012-02-13 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
M - Exercise | −18 833 | 56 499 | −25,00 | ||||
2012-02-13 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
F - Taxes | −7 007 | 66 283 | −9,56 | 118,14 | −827 807 | 7 830 674 | |
2012-02-13 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | 18 833 | 73 290 | 34,58 | ||||
2012-02-10 |
|
4 | BIIB |
BIOGEN IDEC INC.
Restricted Stock Unit |
A - Award | 45 084 | 45 084 | |||||
2010-07-19 | 3 | BIIB |
BIOGEN IDEC INC.
Common Stock |
0 | ||||||||
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 256 915 | −0,01 | 6,84 | −684 | 8 597 299 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 257 015 | −0,01 | 6,78 | −678 | 8 522 562 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −200 | 1 257 115 | −0,02 | 6,90 | −1 380 | 8 674 094 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 257 315 | −0,01 | 6,96 | −696 | 8 750 912 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 257 415 | −0,01 | 6,99 | −699 | 8 789 331 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 257 515 | −0,01 | 6,98 | −698 | 8 777 455 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −200 | 1 257 615 | −0,02 | 6,97 | −1 394 | 8 765 577 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 257 815 | −0,01 | 6,96 | −696 | 8 754 392 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 257 915 | −0,01 | 6,93 | −693 | 8 717 351 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 258 015 | −0,01 | 6,75 | −675 | 8 491 601 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 258 115 | −0,01 | 6,78 | −678 | 8 530 020 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 258 215 | −0,01 | 6,77 | −677 | 8 518 116 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 258 315 | −0,01 | 6,82 | −682 | 8 581 708 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 258 415 | −0,01 | 6,80 | −680 | 8 557 222 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 258 515 | −0,01 | 6,86 | −686 | 8 633 413 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −200 | 1 258 615 | −0,02 | 6,87 | −1 374 | 8 646 685 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −300 | 1 258 815 | −0,02 | 6,83 | −2 049 | 8 597 706 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −106 | 1 259 115 | −0,01 | 6,85 | −726 | 8 624 938 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −100 | 1 259 221 | −0,01 | 6,89 | −689 | 8 676 033 |
2008-02-06 |
|
4 | EXEL |
EXELIXIS INC
Common Stock |
S - Sale | X | −94 | 1 259 321 | −0,01 | 6,85 | −644 | 8 626 349 |
2005-12-14 |
|
4 | EXEL |
EXELIXIS INC
Option (right to buy) |
A - Award | 1 000 000 | 1 000 000 |